AZD-6482 is an inhibitor of p110β PI3K. AZD-6482 inhibits insulin-induced adipocyte glucose uptake in vitro and increases glucose homeostasis in vivo. Additionally, AZD-6482 exhibits antithrombotic activity without increasing bleeding time or blood loss in other animal models.
| Cas No. | 1173900-33-8 |
|---|---|
| Purity | ≥98% |
| Formula | C22H24N4O4 |
| Formula Wt. | 408.45 |
| IUPAC Name | 2-[[(1R)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoic acid |
| Solubility | DMSO 82 mg/mL (200.75 mM) Ethanol 10 mg/mL (24.48 mM) Water Insoluble |
| Appearance | Off-white Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Weigelt B, Warne PH, Lambros MB, et al. PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res. 2013 Jul 1;19(13):3533-44. PMID: 23674493.
Nylander S, Kull B, Björkman JA, et al. Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor. J Thromb Haemost. 2012 Oct;10(10):2127-36. PMID: 22906130.
